Indication: Head and Neck Cancer
An open label Phase II randomized trial of BNT113 in combination with pembrolizumab versus pembrolizumab monotherapy as a first line therapy in patients with unresectable recurrent, or metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) which is positive for human papilloma virus 16 (HPV16+) and expresses PD-L1
Sub-indication: Head and Neck Cancer
Study Type: Drug Study
Principal Investigator: Jaspreet Grewal, M.D.Norton Cancer Institute
Sponsor: Sponsor: BioNTech RNA Pharmaceuticals GmbH
Email for more information: Head&Neck-NCIResearch@nortonhealthcare.org